BridgeMD
New treatment option for Chemotherapy-Induced Peripheral Neuropathy
Official title A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors Post-treatment
ClinicalTrials.gov ID: NCT07365007
What this study is testing
- What it's testing
- This clinical trial studies whether a virtually delivered diet intervention focused on lower added sugar, higher fiber, and higher omega 3 fatty acid (LASO-3) can be used to improve chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors after treatment. Cancer survivors often experience CIPN during and after cancer treatment with neurotoxic chemotherapy.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- 18 years or older
- At least three months since last receiving neurotoxic chemotherapy
- Self-report moderate (≥ 2/4) numbness and tingling on the Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE™)...
- Speak/read English
- Have access to the internet
You likely can't join if
- Pre-existing peripheral neuropathy from any cause
- Plan to begin a new prescription of duloxetine (i.e., first-line treatment for CIPN pain) during the study period
- Are enrolled in symptom management trials that may alter CIPN severity
- High grade inflammatory disease such as lupus, Crohn's disease, or rheumatoid arthritis
- Routine nonsteroidal anti-inflammatory drug (NSAID) or steroid supplementation
- Consuming an average three or more servings of fish per week and/or consuming fish oil capsules containing eicosapentaenoic acid (EPA)+...
See the full eligibility criteria
- 18 years or older
- At least three months since last receiving neurotoxic chemotherapy
- Self-report moderate (≥ 2/4) numbness and tingling on the Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE™) Numbness and Tingling Severity Item in the last week
- Speak/read English
- Have access to the internet
- Pre-existing peripheral neuropathy from any cause
- Plan to begin a new prescription of duloxetine (i.e., first-line treatment for CIPN pain) during the study period
- Are enrolled in symptom management trials that may alter CIPN severity
- High grade inflammatory disease such as lupus, Crohn's disease, or rheumatoid arthritis
- Routine nonsteroidal anti-inflammatory drug (NSAID) or steroid supplementation
- Consuming an average three or more servings of fish per week and/or consuming fish oil capsules containing eicosapentaenoic acid (EPA)+ docosahexaenoic acid (DHA) daily or consuming flax oil capsules daily
- Consuming an average of less than 5 servings of sweets, candy bars, chocolate, doughnuts, cookies, cakes, pie, brownies, ice cream, pastries, or sugar sweetened beverages (e.g., soda or coffee/tea) per week
The study team makes the final eligibility decision.
Where it's taking place
- Ann Arbor, Michigan, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ann Arbor, Michigan, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.